TNF- inhibitor (TNFi) therapies have transformed the treatment of several rheumatic musculoskeletal diseases. However, the majority of TNFi s are immunogenic and consequent anti-drug antibodies formation can impact on both treatment efficacy
inhibitor (TNFi) therapy (a type of advanced arthritis treatment). If Tumor necrosis factor inhibitors (TNFi) are drugs that can stop inflammation
TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these drugs and children exposed to TNFi biologics in utero.
In other words, do we think of TNFi induced lupus and TNFi induced psoriasis as a drug effect or a class effect? Answer from
by SK Peasah 2024 Cited by 1Trends included type of DMARD, class of DMARD (conventional (csDMARDs), biologics [tumor necrosis factor (TNFi) and Non-TNFi), and Janus kinase
by S Atiqi 2024 Cited by 138Depending on the TNFi, different drug-specific epitopes can be identified [reviewed in van Schie et al. (34)]. With the exception of etanercept, all TNFi are
drugs (csDMARDs) is more effective or improves TNFi drug survival compared to TNFi monotherapy. Methods: Five PsA biologics cohorts were investigated
Although studies suggest the drugs are safe during pregnancy, many TNFi, as infection risk is known to be increased with these
Consistent results were seen across both biologic-naïve and TNF inhibitor‑inadequate responder (TNFi-IR) populations. alpha inhibitors (TNFi-
Comments